These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 3773832)

  • 21. Barbiturate physical dependence in mice: effects of neuroleptics and diazepam on the withdrawal syndrome.
    Belknap JK
    Clin Toxicol; 1978; 12(4):427-34. PubMed ID: 26494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous intraperitoneal infusion of pentobarbital: a model of barbiturate dependence in the rat.
    Yutrzenka GJ; Patrick GA; Rosenberger W
    J Pharmacol Exp Ther; 1985 Jan; 232(1):111-8. PubMed ID: 4038416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical dependence to barbital compared to pentobarbital. IV. Influence of elimination kinetics.
    Boisse NR; Okamoto M
    J Pharmacol Exp Ther; 1978 Mar; 204(3):526-40. PubMed ID: 564953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient diffuse cerebral hypoperfusion in Tc-99m HMPAO SPECT of the brain during withdrawal syndrome following acute barbiturate poisoning.
    Kamijo Y; Soma K; Kondo R; Ohwada T
    Vet Hum Toxicol; 2002 Dec; 44(6):348-50. PubMed ID: 12458639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association.
    McLean W; Boucher EA; Brennan M; Holbrook A; Orser R; Peachey J; Sellers E
    Can J Clin Pharmacol; 2000; 7(4):191-7. PubMed ID: 11118965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Slight abstinence symptoms].
    Vaag UH
    Ugeskr Laeger; 1970 Oct; 132(40):1875-7. PubMed ID: 5469494
    [No Abstract]   [Full Text] [Related]  

  • 27. Barbiturate anesthesia and alcohol tolerance in a rat model.
    Curran MA; Newman LM; Becker GL
    Anesth Analg; 1988 Sep; 67(9):868-71. PubMed ID: 3414998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute liver failure following tetrabamate].
    Binder D; Jost R; Flury R; Salomon F
    Schweiz Med Wochenschr; 1995 May; 125(19):965-9. PubMed ID: 7761807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal drug use and the effectiveness of pharmacotherapy for neonatal abstinence.
    Tunis SL; Webster DM; Izes JK; Finnegan LP
    NIDA Res Monogr; 1984; 55():158. PubMed ID: 6443372
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds.
    Loder E; Biondi D
    Headache; 2003 Sep; 43(8):904-9. PubMed ID: 12940814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barbiturate physical dependence in mice: effects on body temperature regulation.
    Belknap JK; Mitchell MA
    J Pharmacol Exp Ther; 1981 Sep; 218(3):647-52. PubMed ID: 7196449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical dependence produced by long duration, low dose chronic barbital treatment.
    Okamoto M; Hinman DJ
    Subst Alcohol Actions Misuse; 1984; 5(2):97-103. PubMed ID: 6540898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical dependence to barbital compared to pentobarbital. II. Tolerance characteristics.
    Boisse NR; Okamoto M
    J Pharmacol Exp Ther; 1978 Mar; 204(3):507-13. PubMed ID: 564951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification.
    Kawasaki SS; Jacapraro JS; Rastegar DA
    J Subst Abuse Treat; 2012 Oct; 43(3):331-4. PubMed ID: 22285834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of individual variations in drug elimination kinetics for production of pentobarbital physical dependence.
    Okamoto M; Hinman DJ
    J Pharmacol Exp Ther; 1983 Jul; 226(1):52-6. PubMed ID: 6683313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal.
    Greenblatt DJ; Gross PL; Harris J; Shader RI; Ciraulo DA
    J Clin Psychiatry; 1978 Aug; 39(8):673-5. PubMed ID: 681307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Withdrawal symptoms from chronic use of low-dose barbiturates.
    Epstein RS
    Am J Psychiatry; 1980 Jan; 137(1):107-8. PubMed ID: 7352542
    [No Abstract]   [Full Text] [Related]  

  • 38. Barbiturate withdrawal.
    JAMA; 1979 Apr; 241(14):1447. PubMed ID: 430676
    [No Abstract]   [Full Text] [Related]  

  • 39. Pentobarbital for severe gamma-butyrolactone withdrawal.
    Sivilotti ML; Burns MJ; Aaron CK; Greenberg MJ
    Ann Emerg Med; 2001 Dec; 38(6):660-5. PubMed ID: 11719746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenobarbital disposition in the neonate.
    Garrettson LK
    Addict Dis; 1975; 2(1-2):179-85. PubMed ID: 1163361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.